-
1 Comment
Shanghai MicroPort Endovascular MedTech Co., Ltd is currently in a long term uptrend where the price is trading 34.7% above its 200 day moving average.
From a valuation standpoint, the stock is 362.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 44.5.
Shanghai MicroPort Endovascular MedTech Co., Ltd's total revenue rose by 64.9% to $142M since the same quarter in the previous year.
Its net income has increased by 78.7% to $52M since the same quarter in the previous year.
Finally, its free cash flow grew by 182.2% to $67M since the same quarter in the previous year.
Based on the above factors, Shanghai MicroPort Endovascular MedTech Co., Ltd gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| ISIN | CNE100003MJ5 |
| Industry | Medical Devices |
| CurrencyCode | CNY |
| Exchange | SHG |
| Beta | 0.28 |
|---|---|
| Dividend Yield | 1.0% |
| Target Price | 235.5 |
| PE Ratio | 37.43 |
| Market Cap | 14B |
Shanghai MicroPort Endovascular MedTech Co., Ltd. develops, manufactures, and sells technologies and products in the healthcare business. The company primarily offers solutions for aortic and peripheral diseases. Its products include TAA and AAA stent graft systems, balloon inflation catheters, and PTA balloon dilatation catheters. The company was founded in 2012 and is based in Shanghai, the People's Republic of China. Shanghai MicroPort Endovascular MedTech Co., Ltd. is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688016.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
